In conclusion, lack of mature mDCs in ITD+ FD patient samples in combination with the incomplete regeneration of mDCs during remission and higher secretion of IL-10 and stress cytokines (TNF-α, IL-6, and IL-1β) in patients who relapsed strengthen the hypothesis of immunomodulatory changes during the course of ITD+ AML relapse. This evidence concerns the gene IL6 and acute myeloid leukemia.